TissueGen to Showcase How ELUTE® Fiber Enables the Future of Medicine at MD&M East 2016

07 Jun TissueGen to Showcase How ELUTE® Fiber Enables the Future of Medicine at MD&M East 2016

Supports Groundbreaking Applications in Advanced Drug Delivery, Nerve Regeneration, and Tissue Engineering

WHO: TissueGen® Inc., developer of ELUTE® fiber, enables controlled sustained delivery of sensitive pharmaceuticals and biologics from biodegradable fibers for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen works with leading pharmaceutical, therapeutic, and medical device companies to develop fiber and textile medical devices for use in drug delivery applications such as small diameter vascular grafts and stents, tissue and nerve regeneration, orthopedic devices and sutures.

WHAT: Come learn how ELUTE® fiber enables medical device developers to achieve breakthroughs across a broad range of medical applications at MD&M East 2016. TissueGen representatives will be at the show to discuss how ELUTE fiber’s patented manufacturing process enables controlled sustained delivery of the broadest range of temperature-sensitive pharmaceuticals and biologics ever possible via biodegradable fiber-based devices.

ELUTE fiber is developed and manufactured in an ISO Class 7 clean room facility to support compliance with FDA cGMP requirements for manufacturing drug product. Earlier this year TissueGen was awarded ISO13485:2003 certification following significant investment in its quality management system and upgrades to its research, development and production infrastructure.

Visit the company’s redesigned website at www.tissuegen.com for more product information.

WHERE:
MD&M East
Booth 1570
Javits Convention Center
New York, NY

WHEN: MD&M East will take place from June 14-16, 2016.

To schedule a briefing, please contact Jordan Bouclin at Jordan.bouclin@svmpr.com or (401)490-9700.

About TissueGen

TissueGen® Inc. is the developer of ELUTE® fiber, a groundbreaking biodegradable fiber format for advanced drug delivery, nerve regeneration, and tissue engineering. TissueGen has more than four decades of cumulative experience in extruding biodegradable polymer fibers with broad drug delivery capabilities. ELUTE fiber can directly replace standard fibers used in biodegradable textiles currently on the market and provide significantly improved clinical outcomes by delivering therapeutic agents directly at the site of the implant.  By delivering drugs and growth factors at the site of implantation, ELUTE fiber enables medical devices to guide the body’s healing and regenerative processes. For more information, please visit www.tissuegen.com.

# # #

 

For more information contact:

Jordan Bouclin
SVM Public Relations
401-490-9700
jordan.bouclin@svmpr.com

 

No Comments

Sorry, the comment form is closed at this time.